eXoZymes, Inc. (EXOZ) - Total Assets
Based on the latest financial reports, eXoZymes, Inc. (EXOZ) holds total assets worth $7.72 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of eXoZymes, Inc. for net asset value and shareholders' equity analysis.
eXoZymes, Inc. - Total Assets Trend (2021–2024)
This chart illustrates how eXoZymes, Inc.'s total assets have evolved over time, based on quarterly financial data.
eXoZymes, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
eXoZymes, Inc.'s total assets of $7.72 Million consist of 83.0% current assets and 17.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.6% |
| Accounts Receivable | $737.28K | 5.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how eXoZymes, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EXOZ stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: eXoZymes, Inc.'s current assets represent 83.0% of total assets in 2024, an increase from 44.6% in 2021.
- Cash Position: Cash and equivalents constituted 74.6% of total assets in 2024, up from 23.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 5.7% of total assets.
eXoZymes, Inc. Competitors by Total Assets
Key competitors of eXoZymes, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
eXoZymes, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.53 | 0.25 | 2.32 |
| Quick Ratio | 4.53 | 0.25 | 2.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.37 Million | $-4.38 Million | $834.88K |
eXoZymes, Inc. - Advanced Valuation Insights
This section examines the relationship between eXoZymes, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 7.13 |
| Asset Growth Rate (YoY) | 266.3% |
| Total Assets | $13.03 Million |
| Market Capitalization | $92.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values eXoZymes, Inc.'s assets at a significant premium (7.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: eXoZymes, Inc.'s assets grew by 266.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for eXoZymes, Inc. (2021–2024)
The table below shows the annual total assets of eXoZymes, Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.03 Million | +266.29% |
| 2023-12-31 | $3.56 Million | +32.50% |
| 2022-12-31 | $2.69 Million | +14.47% |
| 2021-12-31 | $2.35 Million | -- |
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, Califor… Read more